$-0.15 EPS Expected for Fennec Pharmaceuticals Inc. (FENC)

March 15, 2018 - By Migdalia James

 $ 0.15 EPS Expected for Fennec Pharmaceuticals Inc. (FENC)

Analysts expect Fennec Pharmaceuticals Inc. (NASDAQ:FENC) to report $-0.15 EPS on March, 29.They anticipate $0.07 EPS change or 87.50 % from last quarter’s $-0.08 EPS. After having $-0.15 EPS previously, Fennec Pharmaceuticals Inc.’s analysts see 0.00 % EPS growth. The stock increased 0.59% or $0.06 during the last trading session, reaching $9.43. About 68,977 shares traded or 190.92% up from the average. Fennec Pharmaceuticals Inc. (NASDAQ:FENC) has 0.00% since March 15, 2017 and is . It has underperformed by 16.70% the S&P500.

Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. The company has market cap of $173.62 million. The Company’s lead product candidate is the Sodium Thiosulfate, a water soluble thiol compound that acts as a chemical reducing agent, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. It currently has negative earnings. The firm was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014.

More notable recent Fennec Pharmaceuticals Inc. (NASDAQ:FENC) news were published by: Seekingalpha.com which released: “Fennec Pharma’s lead product candidate shows treatment benefit in late-stage …” on September 13, 2017, also Globenewswire.com with their article: “Fennec Announces Pricing of Public Offering” published on December 08, 2017, Marketwatch.com published: “Fennec Pharmaceuticals Inc.” on October 15, 2017. More interesting news about Fennec Pharmaceuticals Inc. (NASDAQ:FENC) were released by: Streetinsider.com and their article: “Wedbush Starts Fennec Pharmaceuticals (FENC) at Outperform” published on March 12, 2018 as well as Seekingalpha.com‘s news article titled: “Otonomy’s $525 Million Dive Is Fennec’s Good Fortune” with publication date: November 02, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.